The USFDA has approved the combination of lenvatinib + pembrolizumab as the first-line of treatment for advanced renal cell carcinoma (RCC). The approval was based on the results of CLEAR – a multicenter, open-label, randomized phase-3 trial.
Participants Experimental group: Lenvatinib plus pembrolizumab (n=355) Control group: Sunitinib (n=357) ## Adverse reactions (ADR) in the experimental group were: ## Common ADR - ≥ 20% including fatigue, diarrhea, musculoskeletal pain, hypothyroidism , hypertension , stomatitis , decreased appetite, rash, nausea, decreased weight, dysphonia, proteinuria, palmar-plantar erythrodysesthesia syndrome, abdominal pain, hemorrhagic events, vomiting, constipation, hepatotoxicity, headache, and acute kidney injury. Arterial thrombotic events - 5% Myocardial infarction - 3.4% Cerebrovascular accident - 2.3%## The study was reviewed using Real-Time Oncology…
